Psychedelic Research in
Albania
Albania currently appears to have no linked psychedelic trials, active linked trials, linked stakeholders or linked events in Blossom's database. In practice, the country context suggests a tightly controlled environment: classic psychedelics and related compounds are treated as controlled psychotropic or narcotic substances, while routine hospital ketamine use exists only in standard anaesthesia and emergency care settings rather than as a psychedelic mental-health pathway.
Key Insights
A concise read of the policy, research, and stakeholder signals shaping psychedelic medicine in Albania.
- 1
The evidence supports a restrictive controlled-substances regime rather than an established psychedelic medicine pathway. ([who.int](https://www.who.int/our-work/access-to-medicines-and-health-products/controlled-substances?utm_source=openai))
- 2
No public record located in this search suggests a domestic psilocybin, MDMA or similar psychedelic trial infrastructure in Albania. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/42049943/?utm_source=openai))
- 3
WHO guidance underscores that countries must balance medical/scientific availability with abuse control, which fits Albania's likely posture for any future research permissions. ([who.int](https://www.who.int/our-work/access-to-medicines-and-health-products/controlled-substances?utm_source=openai))
- 4
The absence of a visible esketamine registration or reimbursement pathway means ketamine/esketamine should not be assumed to be available for psychedelic-assisted care. ([akbpm.gov.al](https://akbpm.gov.al/?utm_source=openai))
- 5
Any future policy movement would likely come through medicines regulation and controlled-substances administration rather than a dedicated psychedelic policy framework. ([who.int](https://www.who.int/our-work/access-to-medicines-and-health-products/controlled-substances?utm_source=openai))
Research Snapshot
Blossom currently keeps Albania as a country index, but no psychedelic clinical trials, stakeholders or events are linked to this country in the database yet.
Missing linked records are database coverage signals, not proof that no local policy discussion, care or informal activity exists.
- Active trials
- 0
- Total trials
- 0
- Stakeholders
- 0
- Events
- 0
None marked active
No linked trials
No linked stakeholders
No linked events
Top Compounds
No headline compound signal is available from linked country trials yet.
Top Study Topics
No study-topic signal is available from linked country trials yet.
Medical Access Snapshot
Most classical and novel psychedelic compounds (psilocybin, MDMA, DMT family, mescaline, 2C-X, ibogaine, ayahuasca) are listed as controlled/hallucinogenic substances in Albanian law and have no authorized medical use outside approved research. Ketamine is routinely procured and used in Albanian hospitals for anesthesia and emergency care but use for psychiatric indications is off-label and not part of any publicly reimbursed, standardized psychedelic-assisted therapy program. Esketamine (Spravato) does not appear on Albania's national...
Regulatory Status
Albania should be treated as a medical-only, privately constrained jurisdiction for psychedelic-related compounds: WHO/UN drug-control materials indicate that controlled psychotropic and narcotic substances are subject to international medical-and-scientific controls, and Albanian criminal law materials show penalties for illegal trafficking of narcotic/psychotropic substances. Blossom's snapshot that psilocybin, MDMA, DMT-family substances, mescaline, 2C-X, ibogaine and ayahuasca have no authorised medical use outside approved research is consistent with this framework; however, I could not verify a specific Albanian psychedelic research pathway or any public reimbursement route, so those access details should remain cautious. ([who.int](https://www.who.int/our-work/access-to-medicines-and-health-products/controlled-substances?utm_source=openai))
Country Details
- Region
- Europe
- Last updated
- 4 May 2026
Country Report
Medical Only (Private)Medical Access and Reimbursement
Most classical and novel psychedelic compounds (psilocybin, MDMA, DMT family, mescaline, 2C-X, ibogaine, ayahuasca) are listed as controlled/hallucinogenic substances in Albanian law and have no authorized medical use outside approved research. Ketamine is routinely procured and used in Albanian...
Open access guide →